Shares of medical device company Teleflex slide despite 1st-quarter earnings that beat expectations on Wall Street and re-affirmed guidance for the rest of the year.
Investors reacted to a sold 1st quarter from medical device company Teleflex (NYSE:TFX) by sending share prices down some 4% today, despite earnings that beat expectations and confirmed sales and profit guidance for the rest of the year.
The FDA gives Teleflex a nod to begin distributing its Arrow VPS G4 device for placing PICC lines during heart procedures.
Teleflex (NYSE:TFX) said its ultrasound device, the Arrow VPS G4, will be available in the U.S. in the 2nd quarter this year.
The FDA cleared the device for use in conjunction with Teleflex's disposable Arrow VPS Stylet.
The new Arrow device uses micro-doppler ultrasound and intravascular electrocardiography to locate a specific location of the vena cava and cavo-atrial junction. Finding this small location in the heart is important when placing a peripherally inserted central catheter.
Teleflex subsidiary LMA PacMed enters a 3 year contract to provide the Healthscope Group of 46 Australian hospitals with airway management devices.
Teleflex (NYSE:TFX) will provide the Healthscope Group of Hospitals with the laryngeal mask line from the acquired Australian subsidiary company, LMA PacMed. The contract gives LMA PacMed preferred supplier status for 3 years with an option of an additional 2 years.
The contract for these airway management devices and associated products will go to Healthscope Group's 46 facilities throughout Australia.
HealthTrust signs 2 new deals for Teleflex's ligation products and Ivera's disinfection system.
Group purchasing organization HealthTrust hammered out deals with Teleflex (NYSE:TFX) and Ivera Medical.
Echo Therapeutics aims to raise some $10 million from a public offering of 10.3 million shares of stock at 75¢ apiece.
Echo Therapeutics (NSDQ:ECTE) priced its public stock offering at 75¢ per share, saying it expects to raise about $10 million in gross proceeds.
The 13.3 million-share offering includes a 45-day over-allotment option for bookrunner Aegis Capital for another 2 million shares.